Mohammadbagher HOSSEİNİ, Hamid AZAMPOUR, Sina RAEİSİ, Meysam BEHTARİ, Hadi VALIZADEH, Roya SABOOHİ

The effects of enteral artificial amniotic fluid-containing erythropoietin on short term outcomes of preterm infants

Necrotizing Enterocolitis (NEC) is a common devastating gastrointestinaldisease, which usually develops in premature infants. Erythropoietin (EPO) asa hematopoietic hormone produced by the kidney can also be naturally foundin amniotic fluid and breast milk. There is some evidence that supports thecontribution of EPO in the prevention of inflammation and intestinal tissuerepair. This study was aimed to determine if oral administration of artificialamniotic fluid with or without EPO would protect preterm infants against NECand improve the certain neonatal outcomes. In this study, 150 preterm infantswith gestational age 28 weeks or less and birth weight 1250 grams or lesswere enrolled. The infants were divided randomly into 3 groups: 1) Controlgroup (n=50) with routine feeding protocol without any administration; 2)Amniotic fluid group (n=50) with 5mL/kg synthetic amniotic fluid; 3) EPOgroup (n=50) with RhuEPO dissolved in the synthetic amniotic fluid. Theadministrations of the study solution were started 3 days after the birth andwere continued for 3 weeks (21 days). The infants in the study groups werefollowed up until discharge and the frequency of NEC, mortality, and othercomplications of the disease among the groups were compared. The mortalityrate in preterm infants of the amniotic fluid and EPO groups were significantlylower than in the control group (p=0.027). We couldn’t find any significantdifferences in the frequency of NEC and other complications among the threestudy groups. The administration of synthetic amniotic fluid (with or withoutEPO) in preterm infants may decrease the mortality rate. Use of EPO insynthetic amniotic fluid did not affect the frequency of NEC.

PDF

___

1. Sugiura T, Kouwaki M, Goto K, et al. Effects of exchange transfusion on cytokine profiles in necrotizing enterocolitis. Pediatr Int 2012; 54: 931- 933.

2. Atici A, Karaman A, Zenciroglu A, et al. Factors affecting mortality in stage 3b necrotizing enterocolitis. Turk J Pediatr 2014; 56: 133-137.

3. Yurdakök M. What next in necrotizing enterocolitis? Turk J Pediatr 2008; 50: 1-11.

4. Garg PM, Ravisankar S, Bian H, Macgilvray S, Shekhawat PS. Relationship between packed red blood cell transfusion and severe form of necrotizing enterocolitis: Acase control study. Indian Pediatr 2015; 52: 1041-1045.

5. Thompson AM, Bizzarro MJ. Necrotizing enterocolitis in newborns: Pathogenesis, prevention and management. Drugs 2008; 68: 1227-1238.

6. Morgan J, Young L, McGuire W. Slow advancement of enteral feed volumes to prevent necrotising enterocolitis in very low birth weight infants. Cochrane Database Syst Rev 2015:CD001241.

7. Dördelmann M, Rau G, Bartels D, et al. Evaluation of portal venous gas detected by ultrasound examination for diagnosis of necrotising enterocolitis. Arch Dis Child Fetal Neonatal Ed 2009; 94: F183-F187.

8. Heida FH, Stolwijk L, Loos MLHJ, et al. Increased incidence of necrotizing enterocolitis in the Netherlands after implementation of the new Dutch guideline for active treatment in extremely preterm infants: Results from three academic referral centers. J Pediatr Surg 2017; 52: 273-276.

9. Ahle M, Drott P, Andersson RE. Epidemiology and trends of necrotizing enterocolitis in Sweden: 1987- 2009. Pediatrics 2013; 132: e443-e451.

10. Holman RC, Stehr-Green JK, Zelasky MT. Necrotizing enterocolitis mortality in the United States, 1979-85. Am J Public Health 1989; 79: 987-989.

11. Narayanan M, Schlueter M, Clyman RI. Incidence and outcome of a 10-fold indomethacin overdose in premature infants. J Pediatr 1999; 135: 105-107.

12. Peter C, Feuerhahn M, Bohnhorst B, et al. Necrotising enterocolitis: Is there a relationship to specific pathogens? Eur J Pediatr 1999; 158: 67-70.

13. Boo NY, Cheah IGS. Risk factors associated with necrotising enterocolitis in very low birth weight infants in Malaysian neonatal intensive care units. Singapore Med J 2012; 53: 826-831.

14. Caplan M. Neonatal necrotizing enterocolitis: clinical observations, pathophysiology, and prevention. In: Martin RJ, Fanaroff AA, Walsh MC (eds). Fanaroff and Martin ‘s Neonatal Perinatal Medicine (10th ed) St Lois: Mosby 2014: 1423-1432.

15. Kumral A, Baskın H, Duman N, et al. Erythropoietin protects against necrotizing enterocolitis of newborn rats by the inhibiting nitric oxide formation. Biol Neonate 2003; 84: 325-329.

16. Ledbetter DJ, Juul SE. Erythropoietin and the incidence of necrotizing enterocolitis in infants with very low birth weight. J Pediatr Surg 2000; 35: 178- 182.

17. Shiou SR, Yu Y, Chen S, et al. Erythropoietin protects intestinal epithelial barrier function and lowers the incidence of experimental neonatal necrotizing enterocolitis. J Biol Chem 2011; 286: 12123-12132.

18. Parry G, Tucker J, Tarnow-Mordi W; UK Neonatal Staffing Study Collaborative Group. CRIB II: An update of the clinical risk index for babies score. Lancet 2003; 361: 1789-1791.

19. Sullivan SE, Calhoun DA, Maheshwari A, et al. Tolerance of simulated amniotic fluid in premature neonates. Ann Pharmacother 2002; 36: 1518-1524.

20. Lima-Rogel V, Calhoun DA, Maheshwari A, et al. Tolerance of a sterile isotonic electrolyte solution containing select recombinant growth factors in neonates recovering from necrotizing enterocolitis. J Perinatol 2003; 23: 200-204.

21. Newton NR, Leonard CH, Piecuch RE, Phibbs RH. Neurodevelopmental outcome of prematurely born children treated with recombinant human erythropoietin in infancy. J Perinatol 1999; 19: 403- 406.

22. Lima-Rogel V, Calhoun DA, Maheshwari A, et al. Tolerance of a sterile isotonic electrolyte solution containing select recombinant growth factors in neonates recovering from necrotizing enterocolitis. J Perinatol 2003; 23: 200-204.

23. Calhoun DA, Juul SE, McBryde EV, Veerman MW, Christensen RD. Stability of filgrastim and epoetin alfa in a system designed for enteral administration in neonates. Ann Pharmacother 2000; 34: 1257-1261.

24. Gibbs RS, Blanco JE, St. Clair PJ, Castaneda YS. Quantitative bacteriology of amniotic fluid from women with clinical intraamniotic infection at term. J Infect Dis 1982; 145: 1-8.

25. Bell MJ, Ternberg JL, Feigin RD, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg 1978; 187: 1-7.

26. Gole GA, Ells AL, Katz X, et al; An International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 2005; 123: 991-999.

27. Papile LA, Munsick-Bruno G, Schaefer A. Relationship of cerebral intraventricular hemorrhage and early childhood neurologic handicaps. J Pediatr 1983; 103: 273-277.

28. Halpérin DS, Wacker P, Lacourt G, et al. Effects of recombinant human erythropoietin in infants with the anemia of prematurity: A pilot study. J Pediatr 1990; 116: 779-786.

29. Wu IH, Tsai MH, Lai MY, et al. Incidence, clinical features, and implications on outcomes of neonatal late-onset sepsis with concurrent infectious focus. BMC Infect Dis 2017; 17: 465.

30. Moore E, Bellomo R, Nichol A. Erythropoietin as a novel brain and kidney protective agent. Anaesth Intensive Care 2011; 39: 356-372.

31. Qi W, Shen Q, Zhang L, Han LP, Wang S. Study on the inflammatory intervention of erythropoietin on NEC. Exp Ther Med 2016; 11: 2221-2224.

32. Nicaise C, Gire C, Casha P, d’Ercole C, Chau C, Palix C. Erythropoietin as treatment for late hyporegenerative anemia in neonates with Rh hemolytic disease after in utero exchange transfusion. Fetal Diagn Ther 2002; 17: 22-24.

33. Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of doubleblind and open-label follow-up studies. Semin Oncol 1994; 21(2 Suppl 3): 21-28.

34. Katavetin P, Inagi R, Miyata T, et al. Erythropoietin induces heme oxygenase-1 expression and attenuates oxidative stress. Biochem Biophys Res Commun 2007; 359: 928-934.

35. Tramontano AF, Muniyappa R, Black AD, et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 2003; 308: 990-994.

36. Wang L, Zhang Z, Wang Y, Zhang R, Chopp M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004; 35: 1732- 1737.

37. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signalling cascades. Nature 2001; 412: 641- 647.

38. Juul S, Ledbetter D, Joyce A, et al. Erythropoietin acts as a trophic factor in neonatal rat intestine. Gut 2001; 49: 182-189.

39. Shiou SR, Yu Y, Rodriguez RM, Petrof EO, Sun J, Claud EC. 482The Human Milk Factor Erythropoietin Protects Against Necrotizing Enterocolitis (NEC) in Preterm Rats By Maintaining Barrier Function Through Upregulation of Tight Junction Protein Expression. Gastroenterology 2009; 136: A-77-A-78. (AGA Abstracts)

40. Juul SE, Christensen RD. Absorption of enteral recombinant human erythropoietin by neonates. Ann Pharmacother 2003; 37: 782-786.

41. Juul SE. Enterally dosed recombinant human erythropoietin does not stimulate erythropoiesis in neonates. J Pediatr 2003; 143: 321-326.

42. Pasha YZ, Ahmadpour-Kacho M, Hajiahmadi M, Hosseini M. Enteral erythropoietin increases plasma erythropoietin level in preterm infants: A randomized controlled trial. Indian Pediatr 2008; 45: 25-28.

43. Yasmeen B, Chowdhury M, Hoque M, Hossain MM, Jahan R, Akhtar S. Effect of short-term recombinant human erythropoietin therapy in the prevention of anemia of prematurity in very low birth weight neonates. Bangladesh Med Res Counc Bull 2012; 38: 119-123.

44. Romagnoli C, Tesfagabir M, Giannantonio C, Papacci P. Erythropoietin and retinopathy of prematurity. Early Hum Dev 2011; 87(Suppl 1): S39-S42.